This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

45/100

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Biomarkers

Topic: Brain proteins, microglia and lab models

Lack of vitamin D is associated with cognitive decline and Alzheimer's disease. Therefore, we examined the relationship between plasma 25 hydroxyvitamin D [25(OH)D] and plasma phosphorylated-tau 181 (p-tau 181) and neurofilament light chain (NfL) in older adults with memory complaints. This is a cross-sectional analysis of ‘Multidomain Alzheimer Preventive Trial’ baseline data. Subjects were 519 French community-dwelling adults aged 70 + years at risk of dementia with baseline data on plasma 25(OH)D and plasma p-tau 181 and 311 individuals with baseline data on plasma 25(OH)D and plasma NfL. Plasma 25(OH)D, p-tau 181 and NfL were measured using high-sensitivity immune-based assays and associations were explored using adjusted regression analyses. Subjects had a mean (SD) age of 75.2 years (4.3) and 67.6 % were female. The mean (SD) plasma 25(OH)D concentration was 23.5 ng/ml (11.3). The mean (SD) concentrations of plasma p-tau 181 and plasma NfL were 9.9 pg/ml (4.5) and 81.1 pg/ml (34.1) respectively. We did not find significant cross-sectional associations between baseline plasma 25(OH)D and plasma p-tau 181 (Model 3: β-coefficient, 0.0003, 95 % CI: −0.0036, 0.0042, p = 0.879) or plasma 25(OH)D and plasma NfL (Model 3: β-coefficient, −0.0012, 95 % CI: −0.0055, 0.0032, p = 0.599). Age, cognitive status, sex, cardiovascular risk or apolipoprotein ε4 genotype did not modify these non-significant associations. These findings provide evidence that plasma 25(OH)D is not associated with plasma p-tau 181 or plasma NfL in older adults with heightened dementia risk. Longitudinal replication studies are essential to validate these cross-sectional results. • Vitamin D deficiency is associated with an increased risk of Alzheimer's disease. • This is a secondary analysis of the Multidomain Alzheimer Preventive Trial (MAPT). • There were no associations between plasma vitamin D and phosphorylated-tau 181. • There were no associations between plasma vitamin D and neurofilament light chain. • Longitudinal studies are required to validate these cross-sectional findings.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Hooper, C., González, E., Coley, N., Vellas, B., & Guyonnet, S. (2025). Cross-sectional associations of plasma vitamin D with plasma phosphorylated tau-181 and plasma neurofilament light chain in older adults with memory complaints. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2025.107041

Vancouver

Hooper C, González E, Coley N, Vellas B, Guyonnet S. Cross-sectional associations of plasma vitamin D with plasma phosphorylated tau-181 and plasma neurofilament light chain in older adults with memory complaints. Neurobiology of Disease. 2025. doi:10.1016/j.nbd.2025.107041. PMID: 40706903.

BibTeX

@article{hooper2025-40706903,
  author  = {Hooper, Claudie and González, Emmanuel and Coley, Nicola and Vellas, Bruno and Guyonnet, Sophie},
  title   = {{Cross-sectional associations of plasma vitamin D with plasma phosphorylated tau-181 and plasma neurofilament light chain in older adults with memory complaints}},
  journal = {Neurobiology of Disease},
  year    = {2025},
  doi     = {10.1016/j.nbd.2025.107041},
  pmid    = {40706903},
  url     = {https://doi.org/10.1016/j.nbd.2025.107041}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Lack of vitamin D is associated with cognitive decline and Alzheimer's disease.
We did not find significant cross-sectional associations between baseline plasma 25(OH)D and plasma p-tau 181 (Model 3: β-coefficient, 0.0003, 95 % CI: −0.0036, 0.0042, p = 0.879) or plasma 25(OH)D and plasma NfL (Model 3: β-coefficient, −0.0012, 95 % CI: −0.0055, 0.0032, p = 0.599).
Age, cognitive status, sex, cardiovascular risk or apolipoprotein ε4 genotype did not modify these non-significant associations.
These findings provide evidence that plasma 25(OH)D is not associated with plasma p-tau 181 or plasma NfL in older adults with heightened dementia risk.
Longitudinal replication studies are essential to validate these cross-sectional results. • Vitamin D deficiency is associated with an increased risk of Alzheimer's disease. • This is a secondary analysis of the Multidomain Alzheimer Preventive Trial (MAPT). • There were no associations between plasma vitamin D and phosphorylated-tau 181. • There were no associations between plasma vitamin D and neurofilament light chain. • Longitudinal studies are required to validate these cross-sectional findings.

Why it matters

In older adults with memory complaints, the study found no significant cross-sectional associations between plasma vitamin D and either plasma p-tau181 or plasma NfL. This means the data did not show a link between vitamin D levels and these Alzheimer's-related blood markers.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Study designcross-sectional
Participants311
Evidence strengthModerate

How this study scored 45/100

Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Neurobiology of Disease)
Journal's citation record	2 / 4	Neurobiology of Disease: journal h-index 225 (OpenAlex, 2026-10-29)
Study design	4 / 12	A snapshot of people at one point in time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	2 / 4	311 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	0 / 7	Cited 0 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.0 citations a year over 3 year(s) since 2025
Impact for its field and year	0 / 6	Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Sophie Guyonnet: h-index 38 (OpenAlex, whole career)
Institution's track record	2 / 3	Inserm: institution h-index 1,988 (OpenAlex)
Multicenter collaboration	2 / 3	OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40706903)
Free to read	2 / 2	Free to read
Total	45 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Biomarkers

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →